Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lewis Barry Silverman, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Lewis Silverman and Andrew Place.
Lewis Silverman
Connection Strength
3.082
Andrew Place
  1. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062.
    View in: PubMed
    Score: 0.754
  2. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90.
    View in: PubMed
    Score: 0.639
  3. Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 Apr; 69(4):e29542.
    View in: PubMed
    Score: 0.245
  4. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 11 01; 39(31):3496-3505.
    View in: PubMed
    Score: 0.236
  5. Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885.
    View in: PubMed
    Score: 0.228
  6. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719.
    View in: PubMed
    Score: 0.225
  7. A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. Pediatr Blood Cancer. 2019 04; 66(4):e27568.
    View in: PubMed
    Score: 0.198
  8. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018 06 26; 2(12):1449-1458.
    View in: PubMed
    Score: 0.192
  9. Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. Br J Haematol. 2022 Mar 21.
    View in: PubMed
    Score: 0.062
  10. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Adv. 2022 01 11; 6(1):72-81.
    View in: PubMed
    Score: 0.061
  11. Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021 05 06; 137(18):2463-2480.
    View in: PubMed
    Score: 0.058
  12. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 06; 11(6):1424-1439.
    View in: PubMed
    Score: 0.057
  13. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017 Feb 15; 23(4):1012-1024.
    View in: PubMed
    Score: 0.043
  14. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
    View in: PubMed
    Score: 0.042
  15. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.